EGFR and non-small cell lung carcinoma: The IMpower 150 trial showed improved OS in EGFR-mutant patients treated with ABCP compared to BCP, but overall, ICIs alone or with chemotherapy have limited efficacy in EGFR-mutant NSCLC [10, 76, 77].